These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 20097949)
1. [The role of estrogens in Parkinson's disease]. Dziedziejko V; Białecka M; Machoy-Mokrzyńska A; Kłodowska-Duda G; Chlubek D Postepy Hig Med Dosw (Online); 2009 Dec; 63():627-33. PubMed ID: 20097949 [TBL] [Abstract][Full Text] [Related]
2. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Morissette M; Al Sweidi S; Callier S; Di Paolo T Mol Cell Endocrinol; 2008 Aug; 290(1-2):60-9. PubMed ID: 18515001 [TBL] [Abstract][Full Text] [Related]
3. The use of estrogen in the treatment of Parkinson's disease. Tsang KL; Jiang H; Ramsden DB; Ho SL Parkinsonism Relat Disord; 2001 Oct; 8(2):133-7. PubMed ID: 11489678 [No Abstract] [Full Text] [Related]
4. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease. Liu B; Dluzen DE Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209 [TBL] [Abstract][Full Text] [Related]
5. Advances in drug development for Parkinson's disease: present status. Harikrishna Reddy D; Misra S; Medhi B Pharmacology; 2014; 93(5-6):260-71. PubMed ID: 25096413 [TBL] [Abstract][Full Text] [Related]
6. Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both? Saunders-Pullman R Endocrine; 2003 Jun; 21(1):81-7. PubMed ID: 12777707 [TBL] [Abstract][Full Text] [Related]
8. Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: A contribution to sex-specific neuroprotection by estrogens. Gillies GE; McArthur S Horm Behav; 2010 Jan; 57(1):23-34. PubMed ID: 19538962 [TBL] [Abstract][Full Text] [Related]
10. New insight into the therapeutic role of the serotonergic system in Parkinson's disease. Ohno Y; Shimizu S; Tokudome K; Kunisawa N; Sasa M Prog Neurobiol; 2015 Nov; 134():104-21. PubMed ID: 26455457 [TBL] [Abstract][Full Text] [Related]
11. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. Prediger RD J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024 [TBL] [Abstract][Full Text] [Related]
13. Modulation of endoplasmic reticulum stress in Parkinson's disease. Tsujii S; Ishisaka M; Hara H Eur J Pharmacol; 2015 Oct; 765():154-6. PubMed ID: 26297973 [TBL] [Abstract][Full Text] [Related]
14. [Sleep disturbances in Parkinson's disease]. Boczarska-Jedynak M; Opala G Neurol Neurochir Pol; 2005; 39(5):380-8. PubMed ID: 16273462 [TBL] [Abstract][Full Text] [Related]
15. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. Fumagalli F; Racagni G; Riva MA Pharmacogenomics J; 2006; 6(2):95-104. PubMed ID: 16402079 [TBL] [Abstract][Full Text] [Related]
16. Implications for estrogens in Parkinson's disease: an epidemiological approach. Ragonese P; D'Amelio M; Savettieri G Ann N Y Acad Sci; 2006 Nov; 1089():373-82. PubMed ID: 17261781 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. Emborg ME J Neurosci Methods; 2004 Oct; 139(2):121-43. PubMed ID: 15488225 [TBL] [Abstract][Full Text] [Related]
18. [Problems and future perspectives in the treatment of Parkinson's disease]. Hens L; Hellemans J Tijdschr Gerontol Geriatr; 1982 Aug; 13(4):147-54. PubMed ID: 6127822 [TBL] [Abstract][Full Text] [Related]
19. Sex differences in Parkinson's disease and other movement disorders. Smith KM; Dahodwala N Exp Neurol; 2014 Sep; 259():44-56. PubMed ID: 24681088 [TBL] [Abstract][Full Text] [Related]
20. Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders. Quik M; Bordia T; Zhang D; Perez XA Int Rev Neurobiol; 2015; 124():247-71. PubMed ID: 26472532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]